稳健医疗(300888) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥2,322,337,445.27, representing a 2.37% increase compared to ¥2,268,544,975.62 in the same period last year[4] - Net profit attributable to shareholders decreased by 25.69% to ¥357,101,020.81 from ¥480,582,571.42 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥328,127,955.96, down 27.89% from ¥455,065,047.62 in the previous year[4] - The company achieved total revenue of 2.322 billion RMB in Q1 2022, a year-on-year increase of 2.37%, while the net profit attributable to shareholders was 357 million RMB, a decrease of 25.69%[15] - Net profit for Q1 2022 was CNY 357,566,496.99, compared to CNY 480,806,327.63 in the same period last year, representing a decrease of approximately 25.6%[23] - Earnings per share for Q1 2022 were CNY 0.84, down from CNY 1.13 in the previous year[24] - The total comprehensive income for Q1 2022 was CNY 357,341,042.57, down from CNY 481,013,637.78 in the same period last year[24] Cash Flow and Investments - The net cash flow from operating activities increased significantly by 111.45% to ¥397,234,802.12 compared to ¥187,866,670.61 in the same period last year[4] - The total cash inflow from operating activities for the current period is CNY 2,497,227,365.63, an increase from CNY 2,273,919,182.07 in the previous period, representing a growth of approximately 9.8%[26] - The net cash flow from operating activities is CNY 397,234,802.12, significantly higher than CNY 187,866,670.61 in the previous period, indicating a year-over-year increase of about 111.1%[26] - The cash outflow from investing activities totals CNY 2,161,949,263.38, compared to CNY 2,191,853,055.24 in the previous period, showing a slight decrease of approximately 1.4%[26] - The net cash flow from investing activities is negative at CNY -479,044,186.87, contrasting with a positive CNY 355,651,431.22 in the previous period[26] - The company received CNY 1,644,215,024.46 from investment recoveries, a decrease from CNY 2,520,000,000.00 in the previous period, indicating a decline of about 34.7%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,627,200,963.44, a 2.72% increase from ¥13,266,610,200.37 at the end of the previous year[4] - Total liabilities as of Q1 2022 amounted to CNY 2,786,048,110.83, an increase from CNY 2,579,501,987.63 year-over-year[21] - Total equity for Q1 2022 was CNY 10,841,152,852.61, compared to CNY 10,687,108,212.74 in the previous year[21] - Cash and cash equivalents decreased to approximately 3.85 billion RMB from 4.27 billion RMB at the beginning of the year[18] - Total assets increased to approximately 13.63 billion RMB, up from 13.27 billion RMB at the beginning of the year[19] Sales and Market Performance - Overseas sales accounted for 23.28% of total sales, down from 43.72% in the same period last year, with overseas sales of 327 million RMB, a year-on-year decline of 47.66%[16] - Domestic sales reached 1.079 billion RMB, representing a year-on-year growth of 34.00% and a quarter-on-quarter increase of 100.85%[16] - The health and wellness consumer products segment generated 890 million RMB in revenue, an increase of 8.76% year-on-year, despite some disruptions due to pandemic control measures[16] - The company reported a 15.08% increase in wound care and dressing products, driven by product innovation and structural adjustments[16] - The high-end wound dressing products saw a significant growth of 64.59%, attributed to increased investment in R&D and marketing[16] - The company plans to consolidate the acquisition of 55% of Longtai Medical in Q3 2022, which is expected to enhance sales and market share of high-end wound dressing products[16] Expenses - Total operating costs for Q1 2022 were CNY 1,901,908,249.46, up from CNY 1,691,851,962.34 year-over-year[22] - Research and development expenses for Q1 2022 were CNY 94,410,776.54, slightly down from CNY 99,190,124.31 year-over-year[22] - The company reported a decrease in sales expenses to CNY 469,795,921.04 from CNY 392,315,649.65 in the previous year[22] - The cash paid to employees increased to CNY 467,078,949.68 from CNY 367,313,551.12, marking an increase of approximately 27.2%[26] Inventory - The company’s inventory rose to approximately 1.64 billion RMB, compared to 1.60 billion RMB at the beginning of the year[19] Audit - The company did not conduct an audit for the first quarter report[28]